Industry's Rebate Arms Race: Securing Market Access At A Cost
This article was originally published in Scrip
Rebates have become industry's go-to for securing market access for drugs in competitive therapeutic areas in the US. But as payers push back, competitive rebating is intensifying and eating into the bottom line.
Register for our free email digests: